Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy, a non-invasive therapy for the treatment of major depressive disorder (MDD) and other mental health disorders, in the United States. It also offers treatment for obsessive compulsive disorder. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. It offers Spravato (esketamine nasal spray) at select TMS Centers to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It operates a network of outpatient mental health service centers that specialize in TMS treatment across the United States. It owns and operates about 149 TMS Centers in the Commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Greenbrook TMS Inc does not pay a dividend.
Price/Cash Flow (TTM)